MedTrace Logo

Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?

NCT01091714 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-10-05

No results posted yet for this study

Summary

To demonstrate that RBC saturation of the Omega-3 fatty acids reaching cardioprotective levels as proven with the HS-Omega-3 Index test will be achieved most efficiently depending on a specific product utilized within this study.

Conditions

  • Cardioprotective Levels

Interventions

DIETARY_SUPPLEMENT

Omega-3

Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

DIETARY_SUPPLEMENT

Omega-3

Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

DIETARY_SUPPLEMENT

Omega-3

Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

Sponsors & Collaborators

  • Bucci Laser Vision Institute

    lead OTHER

Principal Investigators

  • Frank A Bucci, Jr., MD · Bucci Laser Vision Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01091714 on ClinicalTrials.gov